

Publicazioni

Autore o co-autore di 66 pubblicazioni in riviste internazionali peer-reviewed. Impact Factor totale: 294; Impact Factor come primo o ultimo autore: 177 , esclusa la corrispondenza (JCR-ISI WEB 2012). H Index al Luglio 2013: 24 (Anne-Wil Harzing), total citations: 2871. E' inoltre autore o coautore di 7 capitoli di libro.

1. Dieci MV, Criscitiello C, Goubar A, Viale G, Conte PF, **Guarneri V**, Ficarra G, Mathieu MC, Delalogue S, Andre F, Curigliano G. Prognostic value of tumor infiltrating lymphocytes (TILs) on residual disease after primary chemotherapy for triple-negative breast cancer (TNBC) patients. *Ann Oncol*, in press **(IF: 7,384)**
2. **Guarneri V**, Generali DG, Frassoldati A, Artioli F, Boni C, Cavanna L, Tagliafico E, Maiorana A, Bottini A, Cagossi K, Bisagni G, Piacentini F, Ficarra G, Bettelli S, Roncaglia E, Nuzzo S, Swaby R, Ellis C, Holford C, Conte PF. Double-blind, placebo-controlled, multicenter randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, HER2-negative, operable breast cancer. *J Clin Oncol*, in press **(IF: 18.038)**
3. **Guarneri V**, Dieci MV, Barbieri E, Piacentini F, Omarini C, Ficarra G, Bettelli S, Conte PF. Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2 positive breast cancer patients. *Ann Oncol*, 2013 Sep 7. [Epub ahead of print]**(IF: 7,384)**
4. **Guarneri V**, Dieci MV, Conte PF. Relapsed triple-negative breast cancer: challenges and treatment strategies. *Drugs*, 2013 Aug;73(12):1257-65 **(IF 4,663)**
5. Collovà E, Ciccarese M, Di Maio M, Fabi A, Generali D, **Guarneri V**, La Verde N, Moschetti L, Salesi N, Scandurra G. l'attualità nella pratica clinica del trattamento del carcinoma della mammella avanzato. *Expert Review of Anticancer Therapy*, Special Issue n1 , 2013
6. Dieci MV, **Guarneri V**, Conte PF. The Future of Chemotherapy in the Era of Personalized Medicine. *Current Breast Cancer Reports* 2013, 5 Issue 1, 57-68
7. Dieci MV, Barbieri E, Piacentini F, Ficarra G, Bettelli S, Dominici M, Conte PF, **Guarneri V**. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis. *Ann Oncol* 2013 Jan;24(1):101-8 **(IF: 7,384)**
8. Cortesi L, Marcheselli L, **Guarneri V**, Cirilli C, Braghiroli B, Toss A, Sant M, Ficarra G, Conte PF, Federico M. Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. *Int J Cancer*. 2013 Jan 15;132(2):E58-65. **(IF 6.198)**
9. **Guarneri V**, Conte P. The Next Generation of Biologic Agents: Therapeutic Role in Relation to Existing Therapies in Metastatic Breast Cancer. *Clin Breast Cancer* 2012 Jun;12(3):157-66 **(IF: 2.422)**
10. **Guarneri V**, Frassoldati A, Bottini A, Cagossi K, Bisagni G, Sarti S, Ravaioli A, Cavanna L, Giardina G, Musolino A, Untch M, Orlando L, Artioli F, Boni C, Generali DG, Serra P, Bagnalasta M, Marini L, Piacentini F, D'Amico R, Conte PF. Preoperative chemotherapy plus

trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study. *J Clin Oncol*, 2012 Jun 1;30(16):1989-95 (IF: 18.038)

11. Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, **Guarneri V**, D'Amico R. Trastuzumab containing regimens for early breast cancer. *Cochrane Db Syst Rev*, 2012 Apr 18;4:CD006243 (IF: 5.703)
12. **Guarneri V**, Dieci MV, Conte P. Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. *Expert Opin Pharmacother*. 2012 Feb;13(3):395-406. (IF: 2.860)
13. **Guarneri V**, Conte PF. A guided choice for treatment of hormone receptor-positive advanced breast cancer. *Hot Topics Oncol* 2011;5(8):15-20
14. Dieci MV, Barbieri E, Bettelli S, Piacentini F, Omarini C, Ficarra G, Balduzzi S, Dominici M, Conte P, **Guarneri V**. Predictors of HER2 FISH amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. *J Clin Pathol*. 2012 Jun;65(6):503-6 (IF: 2.439)
15. **Guarneri V**, Barbieri E, Conte PF. Biomarkers predicting clinical benefit: facts or fiction? *J Natl Cancer Inst Monogr* 2011;2011(43):63-6.
16. Grisendi G, Bussolari R, Veronesi E, Piccinno S, Burns JS, De Santis G, Loschi P, Pignatti M, Di Benedetto F, Ballarin R, Di Gregorio C, **Guarneri V**, Piccinini L, Horwitz EM, Paolucci P, Conte P, Dominici M. Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers. *Am J Cancer Res*. 2011;1(6):787-805.
17. Alvarez R, **Guarneri V**, Icli F, Johnston S, Khayat D, Loibl S, Martin M, Zielinski C, Conte PF, Hortobagyi GN. Bevacizumab Treatment for Advanced Breast Cancer. *The Oncologist*, 2011;16(12):1684-97(IF: 4.095)
18. F Piacentini, G Rossi, C Casali, A Caldioli, E Barbieri, **V Guarneri**. Primary pulmonary cancer colliding with metastatic breast carcinoma: hitherto unreported cases of cancer-to-cancer metastasis focusing on clinical implications. *Lung Cancer*, 2011 Oct;74(1):145-8 (IF: 3.392)
19. **Guarneri V**, Pecchi A, Piacentini F, Barbieri E, Ficarra G, Tazzioli G, Frassoldati A, Battista R, Canossi B, Mauri C, D'Amico R, Torricelli P. Magnetic resonance imaging and ultrasonography in predicting pathologic extent after preoperative chemotherapy in stage II-III breast cancer. *Ann Surg Oncol*, 2011 Aug;18(8):2150-7. (IF: 4.120)
20. **Guarneri V**, Barbieri E, Dieci MV, Piacentini F, Conte PF. Timing for starting second line therapy in recurrent ovarian cancer. *Expert Rev. Anticancer Ther*, 2011 Jan;11(1):49-55. (IF: 2.066)
21. **Guarneri V**, Barbieri E, Dieci MV, Piacentini F, Conte PF. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. *Cancer Treat Rev*. 2010 Nov;36S3:S62-S66. (IF: 6.024)
22. **Guarneri V**, Miles D, Robert N, Diéras V, Glapsy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte PF. Bevacizumab and osteonecrosis of the jaw: incidence and association with

bisphosphonate therapy in three large prospective trials in advanced breast cancer. ***Breast Cancer Res Treat***, 122(1):181-8, 2010. (IF: 4.469)

23. **Guarneri V**, Barbieri E, Piacentini F, Giovannelli S, Ficarra G, Frassoldati A, Maiorana A , D'Amico R, Conte PF. Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single Institution analysis. ***Int J Biol Marker*** 25(2):104-11. 2010 (IF: 1.592)
24. **Guarneri V**, Barbieri E, Piacentini F, Conte PF Achievements and unmet needs in the management of advanced ovarian cancer. ***Gynecol Oncol*** 117(2):152-8 2010 (IF: 3.929)
25. **Guarneri V**. Letrozole plus lapatinib for postmenopausal patients with HR+/HER2+ breast cancer. ***Expert Rev. Anticancer Ther***, Vol. 9, No. 11, 1549-1557 2009 (IF: 2.066)
26. Frassoldati A, **Guarneri V**, Conte PF. Clinical relevance of endocrine therapy-induced changes in lipid metabolism in breast cancer patients. ***Cancer Biol. Ther.***, 2009 Aug;8(15):1456-8. (IF: 3.287)
27. **Guarneri V**, Conte PF. Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. ***The Oncologist*** 2009 Jul;14(7):645-56 (IF: 4.095)
28. Conte PF, **Guarneri V**. Triple-negative breast cancer: current management and future options. ***Eur J Cancer Supp*** 2009, 7(1): 14-18 (IF 5.536)
29. **Guarneri V**, Piacentini F, Ficarra G , Frassoldati A, D'Amico R, Giovannelli S, Maiorana A , Jovic G, Conte PF. A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. ***Ann Oncol***, 2009 Jul;20(7):1193-8 (IF: 7,384)
30. **Guarneri V**, Giovannelli S, Ficarra G, Bettelli S, Maiorana A, Piacentini F, Barbieri E, Dieci MV, D'Amico R, Jovic G, Conte PF. Comparison of HER-2 and Hormone Receptor expression in primary breast cancer and asynchronous paired metastases: impact on patients' management. ***The Oncologist***, 13:838-44, 2008 (IF: 4.095)
31. **Guarneri V**, Frassoldati A, Bruzzi P, D'Amico R, Belfiglio M, Molino A, Bertetto O, Cascinu S, Cognetti F, Di Leo A, Pronzato P, Conte PF. Multicentric, randomised, phase III trial of 2 different adjuvant chemotherapy regimens plus 3 versus 12 months of trastuzumab in HER2 positive breast cancer patients (Short-HER trial, NCT00629278). ***Clin Breast Cancer*** 8:453-6, 2008 (IF: 2.422)
32. **Guarneri V**, Frassoldati A, Piacentini F, Jovic G, Giovannelli S, Oliva C, Conte PF Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial. ***Clin Breast Cancer***, 8: 192-194, 2008 (IF: 2.422)
33. Frassoldati A, **Guarneri V**, Piacentini F, Jovic G, Giovannelli S, Oliva C, Conte PF. Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB). ***Clin Breast Cancer***, 8:97-100, 2008 (IF: 2.422)
34. **Guarneri V**, Frassoldati A, Ficarra G, Puglisi F, Andretta C, Michelotti A, Cresti N, Boni C, Bisagni G, Berardi R, Battelli N, Santoro A, Banna G, Bottini A, Di Blasio B, Maiorana A,

- Piacentini F, Giovannelli S, Jovic G, Conte PF. Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. *Breast Cancer Res Treat*, 110:127-34, 2008. (IF: 4.469)
35. Hoff AO, Toth B, Altundag K, Johnson M, Warneke C, Nooka A, Sayegh G, **Guarneri V**, Desrouleaux K, Cui J, Adamus A, Gagel RF and Hortobagyi GN. The Frequency and Risk Factors Associated with Osteonecrosis of the Jaw or Maxilla in a Large Population of Cancer Patients Treated with Intravenous Bisphosphonates. *J Bone Miner Res*. 2008 Jun;23(6):826-36. (IF: 6.128)
36. Conte PF, **Guarneri V**, Bengala C. Evolving nonendocrine therapeutic options for metastatic breast cancer: How adjuvant chemotherapy influences treatment. *Clin Breast Cancer* 2007, vol 7, No 11, 841-849 (IF: 2.422)
37. Thomas E, Taberner J, Fornier M, Conte PF, Fumoleau P, Lluch A, Vahdat LT, Bunnell CA, Burris HA, Viens P, Baselga J, Rivera E, **Guarneri V**, Poulart V, Klimovsky J, Lebwohl D, Martin M. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. *J Clin Oncol* 2007, Aug 10;25 (23):3399-406 (IF: 18.038)
38. Conte PF, Bengala C, **Guarneri V**. Controversies of chemotherapy for the treatment of metastatic breast cancer. *Eur J Cancer Supp* 2007 s5 (1):11-16 (IF 5.536)
39. Cristofanilli M, Broglio KR, **Guarneri V**, Jackson S, Fritsche HA, Islam R, Dawood S, Reuben JM, Kau S, Lara JM, Krishnamurthy S, Ueno NT, Hortobagyi GN, Valero V. Circulating Tumor Cells in Metastatic Breast Cancer: Biologic Staging Beyond Tumor Burden. *Clin Breast Cancer*. 2007 Feb;7(6):471-9. (IF: 2.422)
40. **Guarneri V** and Conte PF. Bone health: new horizons in the prevention of cancer-treatment induced bone loss and management of bone metastases. *EJHP Practice* 2006; 6: 69 -70
41. Gonzalez-Angulo AM, **Guarneri V**, Gong Y, Cristofanilli M, Morales-Vasquez F, Sneige N, Hortobagyi GN, Esteva FJ. Downregulation of the Cyclin-Dependent Kinase Inhibitor p27kip1 Might Correlate with Poor Disease-Free and Overall Survival in Inflammatory Breast Cancer. *Clin Breast Cancer*. 2006 Oct;7(4):326-330. (IF: 2.422)
42. **Guarneri V**, Frassoldati A, Giovannelli S, Borghi F, Conte PF. Primary Systemic Therapy for Operable Breast Cancer: A Review of Clinical Trials and Perspectives. *Cancer Lett*. 2007, 248:175-85 (IF 4.258)
43. **Guarneri V**, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, Michaud LB, Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ. Long term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. *J Clin Oncol* 2006, 24: 4107-15 (IF: 18.038)
44. Maur M, **Guarneri V**, Frassoldati A, Conte PF: Primary Systemic Therapy in operable breast cancer: clinical data and biological fall-out. *Ann Oncol* 2006, 17 Suppl 5:v158-v164 (IF: 7,384)
45. **Guarneri V**, Giovannelli S, Conte PF: Bisphosphonates in the treatment of metastatic bone disease from solid tumors. *Supp Pall Cancer Care* 2006, 2: s37-s41

46. **Guarneri V**, Cristofanilli M: Clinical utility of measuring circulating tumor cells in metastatic breast cancer. *Clin Breast Cancer* 2006, 7(1):85-6. (IF: 2.422)
47. Bengala C, Zamagni C, Pedrazzoli P, Matteucci P, Ballestrero A, Da Prada G, Martino M, Rosti G, Danova M, Bregni M, Jovic G, **Guarneri V**, Maur M, Conte PF on behalf of Gruppo Italiano Trapianto Midollo Osseo (GITMO) group: Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study. *Brit J Cancer* 2006, 94 (7):1016-20. (IF: 5.082)
48. **Guarneri V**, Broglio K, Kau S, Cristofanilli M, Buzdar A U, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi G N, Gonzalez-Angulo A M: Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. *J Clin Oncol.* 2006; 24:1037-1044 (IF: 18.038)
49. **Guarneri V**, Donati S, Giovannelli S, Nicolini M, D'Amico R, Conte P F: Renal Safety and Efficacy of Intravenous Bisphosphonates in Patients With Skeletal Metastases Treated for up to Ten Years. *The Oncologist* 2005;10:842-8 (IF: 4.095)
50. Frassoldati A, Maur M, **Guarneri V**, Nicolini M, Conte PF. Predictive value of biological parameters for primary chemotherapy in operable breast cancer. *Clin Breast Cancer* 2005; 6: 315-324 (IF: 2.422)
51. Conte PF, Donati S, Gennari A, **Guarneri V**, Orlandini C, Rondini M, Roncella M, Marini L, Collecchi P, Viacava P, Naccarato AG, Degli Esposti R, Bonardi S, Bottini A, Saracchini S, Tumolo S, Gullo G, Santoro A, Crino L: Primary chemotherapy with Gemcitabine, Epirubicin and Taxol (GET) in operable breast cancer: a phase II study. *Brit J Cancer*, 2005 93: 406-411 (IF: 5.082)
52. Bengala C, **Guarneri V**, Giovannetti E, Lencioni M, Fontana E, Mey V, Fontana A, Boggi U, Del Chiaro M, Danesi R, Ricci S, Mosca F, Del Tacca M, Conte PF. Prolonged fixed dose rate infusion of gemcitabine with autologous hemopoietic support in advanced pancreatic adenocarcinoma. *Brit J Cancer*, 2005 93: 35-40 (IF: 5.082)
53. Bengala C, **Guarneri V**, Ledermann J, Rosti G, Wandt H, Lotz J-H, Cure JH, Orlandini C, Ferrante P, Conte PF, Demirer T on behalf of the Solid Tumor Working Party of the EBMT: High-dose chemotherapy with autologous hemopoietic support for advanced ovarian cancer in first complete remission: retrospective analysis from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT). *Bone Marrow Transplant*, 2005 36:25-31. (IF: 3.541)
54. Conte P, **Guarneri V**. In response to Body letter to the editor regarding "safety of intravenous and oral bisphosphonates and compliance with dosing regimens". *Oncologist*. 2005 May;10(5):318-9. (correspondence)
55. Conte P, **Guarneri V**. In response to Jackson letter to the editor regarding safety of intravenous and oral bisphosphonates and compliance with dosing regimens". *Oncologist*. 2005 May;10(5):315-6. (correspondence)
56. Dominici M, **Guarneri V**, Cafarelli L, Conte PF. Le Cellule Mesenchimali Staminali: un emergente nuovo approccio per la terapia cellulare in campo oncologico. *Trends in Medicine* 2004 4:4, 341-348

57. Conte PF, and **Guarneri V**. Safety of Intravenous and Oral Bisphosphonates and Compliance With Dosing Regimens. *The Oncologist*. 9 Suppl 4:28-37, 2004 (IF: 4.095)
58. Conte PF, **Guarneri V**, Bruzzi P, Prochilo T, Salvadori B, Bolognesi A, Aldrighetti D, Venturini M, Rosso R, Gallo L, Mammoliti S, Carnino F, Vesentini L, Giannessi P, Di Marsico R, Costantini M, Beccaro M, Moyano A, Baldini E: Concomitant versus sequential administration of epirubicin and paclitaxel as first line therapy in metastatic breast cancer: results from the GONO randomized trial. *Cancer* 101 (4): 704-712, 2004 (IF: 5.201)
59. **Guarneri V**, Bengala C, Orlandini C, Gennari A, Donati S, Campani D, Collecchi P, Maur M, Bevilacqua G, Conte PF. Her2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high dose chemotherapy and autologous stem cell support. *Bone Marrow Transplant*. 34(5):413-7, 2004 (IF: 3.541)
60. **Guarneri V**, and Conte PF. The curability of breast cancer and the treatment of advanced disease. *Eur J Nucl Med Mol Imaging*. 31 Suppl 1: S149-61, 2004 (IF: 5.144)
61. Gennari A, Bruzzi P, Orlandini C, Salvadori B, Donati S, Landucci E, **Guarneri V**, Rondini M, Ricci S, Conte PF: Activity of first line epirubicin and paclitaxel in metastatic breast cancer is independent from type of adjuvant therapy. *Br J Cancer* 90(5):962-7, 2004. (IF: 5.042)
62. Bengala C, Danesi R, **Guarneri V**, Pazzagli I, Donati S, Favre C, Fogli S, Biadi O, Innocenti F, Del Tacca M, Mariani M, Conte PF. High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. *Bone Marrow Transplant*. 31(4):275-80, 2003 (IF: 3.541)
63. Gennari A, **Guarneri V**, Landucci E, Orlandini C, Rondini M, Salvadori B, Ricci S, Conte PF. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer. *Clin Breast Cancer*. 3(5):346-52, 2002 (IF: 2.422)
64. Conte P, Gennari A, Landucci E, **Guarneri V**, Donati S, Salvadori B, Bengala C, Orlandini C. New combinations with epirubicin in advanced breast cancer. *Oncology* 15 (5 Suppl 7):24-7, 2001 (IF: 3.188)
65. Conte P, Gennari A, **Guarneri V**, Landucci E, Donati S, Salvadori B, Bengala C, Orlandini C, Baldini E. Epirubicin/taxane combinations in breast cancer: experience from several Italian trials. *Oncology* 15 (5 Suppl 7):21-31, 2001 (IF: 3.188)
66. Bengala C, Pazzagli I, Innocenti F, Donati S, Favre C, Menconi MC, Greco F, Danesi R, Orlandini C, **Guarneri V**, Del Tacca M, Conte PF. High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC). *Ann Oncol*. 12(1):69-74, 2001 (IF: 7,384)

Capitoli

- C. Bengala, **V. Guarneri**, I. Pazzagli: Rischio neoplastico post-trapianto. Ne "I trapianti di pancreas", a cura di U. Boggi e F. Mosca, Edizioni ETS, 2001, pag 225-236. ISBN 88-467-0474-6

- **V. Guarneri**, F Piacentini, PF Conte: Progress in the treatment of Early and Advanced Breast Cancer. In “ Breast Cancer. Nuclear Medicine in Diagnosis and Therapeutic Options”, (E. Bombardieri, G Bonadonna, L Gianni). Springer 2008, ISBN 978-3-540-36780-2
- **V Guarneri**. “Bisphosphonates”, Encyclopedia of Cancer 2nd edition, 2008, pag 364-368, Springer Ed. ISBN 978-3-540-36847-2
- **V. Guarneri**, PF Conte: Acute and subacute toxicities of medical anticancer treatment. ESMO handbook of cancer diagnosis and treatment evaluation, pag 79-99 . Informa Healthcare USA, 2009, ISBN 978-1-841-84703-0
- **V. Guarneri** et al: Bone metastases: Pharmacological treatment. In Osteo-Oncology Textbook, 2010, pag 295-326. Poletto Editore, ISBN 978-88-95033-33-4
- Conte PF, Barbieri E, Dieci MV, **Guarneri V**, Piacentini F. i tumori ginecologici, Oncologia Clinica Principi e Pratica, Vol 4 , pag 1-83, CEA (Casa Editrice Ambrosiana) Selecta Medica. ISBN 978-88-18259-3

Submitted:

- Marinovich ML, Macaskill P, Irwig L, Sardanelli F, Mamounas E, von Minckwitz G, **Guarneri V**, Partridge S, Wright F, Hyuck Choi J, Bhattacharyya M, Martincich L, Yeh E, Londero V, Nehmat Houssami N. Agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy: Individual patient data meta-analysis.
- Dieci MV, Lefebvre C, Scott V, Yin O, Vielh P, Mathieu MC, Laporte M, Marty V, Drusch F, **Guarneri V**, Conte PF, Lacroix L, Delaloge S, André F. Whole exome sequencing of pleiomorphic lobular breast cancers identifies PYGM as novel candidate gene involved in breast cancer.
- Grisendi G, Finetti E, Manganaro D, Cordova N, Montagnani G, Spano C, Prapa M, Guarneri V, Otsuru S, Horwitz EM, Mari G, Massimo Dominici M. A Novel Method To Detect Microparticles From Human Blood
- Califano R, Karamouzis MV, Banerjee S, de Azambuja E, Guarneri V, Hutka M, Jordan K, Kamposioras K, Martinelli E, Corral J, S. Postel-Vinay S, Preusser M, Porcu L, Torri V. Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): a European survey conducted by the European Society for Medical Oncology (ESMO) Young Oncologists Committee.
- Lucarini V, Madrigali S, Lugli R, Maur M, Bertolini F, Fontana A, Masini C, **Guarneri V**, Conte PF, Dominici M. Pazopanib-Induced Heart Failure In A Metastatic Sarcoma Patient: Between Reversible Side Effect and Efficacy